On January 6, 2023 Biotechnology company Fraser Therapeutics has completed attracting Series A investment from domestic venture capital (Press release, Prazer Therapeutics, JAN 6, 2023, View Source;idx=226&page=1&code=news [SID1234635351]). A total of KRW 17 billion was invested, and the corporate value after investment was recognized as approximately KRW 67 billion.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Founded in October 2019, Fraser Therapeutics is challenging new drug development based on ‘SPiDEMTM’, a new platform technology that degrades target proteins. This is not only a new platform that overcomes the shortcomings of bio-based technology, but also an innovative method of targeting untargetable proteins (undruggable targets) in cells that cannot be accessed by any existing method.

Fraser Therapeutics, the first domestic company to build its own TPD Platform (Target Protein Degradation Platform), is pursuing the commercialization of Speedem.

Fraser Therapeutics said, "Based on our research and development know-how and expertise in Cell Signaling Pathway and Epigenetics, we will continue to develop treatments step by step, focusing on the field of immuno-anticancer drugs.